AbbVie Inc. $ABBV is Ferguson Wellman Capital Management Inc.’s 8th Largest Position

Ferguson Wellman Capital Management Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 650,498 shares of the company’s stock after buying an additional 2,813 shares during the period. AbbVie comprises about 2.4% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 8th largest position. Ferguson Wellman Capital Management Inc.’s holdings in AbbVie were worth $148,632,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of ABBV. Brighton Jones LLC lifted its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its position in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares in the last quarter. XTX Topco Ltd purchased a new stake in AbbVie in the 2nd quarter valued at about $3,923,000. Finally, Richmond Investment Services LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $283,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ABBV. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Barclays started coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Up 0.8%

Shares of ABBV stock opened at $206.85 on Thursday. The firm has a market cap of $365.74 billion, a P/E ratio of 87.65, a PEG ratio of 0.71 and a beta of 0.34. The company has a 50 day moving average of $222.17 and a 200-day moving average of $224.62. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the company earned $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a multi‑year partnership with Major League Baseball to expand its “Striking Out Cancer” program nationally — a high‑profile marketing and corporate‑responsibility move that should boost brand visibility and patient/public engagement without near‑term material costs. AbbVie Named Official Pharmaceutical Partner of Major League Baseball
• Positive Sentiment: Analysts and value investors are re‑examining ABBV after recent share weakness; one write‑up frames the pullback as a potential buying opportunity based on long‑term fundamentals and pipeline prospects, which can attract bargain hunters. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?
• Positive Sentiment: AbbVie’s psychiatry pipeline expansion (acquisition of bretisilocin) keeps the company positioned in fast‑growing neuropsychiatric markets; the deal supports longer‑term revenue diversification beyond core immunology and oncology franchises. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Neutral Sentiment: Investor attention and search interest in ABBV have spiked, which can increase short‑term volatility but doesn’t signal direction on its own. Investors Heavily Search AbbVie Inc. (ABBV)
• Neutral Sentiment: Related sector financing (e.g., Gilgamesh Pharma’s Series A) signals investor appetite for neuropsychiatric assets but is peripheral to AbbVie’s near‑term earnings. Gilgamesh Pharma Closes Oversubscribed $60 Million Series A
• Negative Sentiment: Competitive dynamics: analysts highlight that rivals (notably Eli Lilly) are seeing explosive growth from obesity medicines, whereas AbbVie’s near‑term growth remains concentrated in Skyrizi and Rinvoq—this relative growth gap could limit upside and keep valuation under pressure. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.